LMR Partners’s Rein Therapeutics RNTX Stock Holding History

LMR Partners’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-653	Closed	-$71K	–	529
2018 Q2	$71K	Buy	+653	New	+$73.9K	﹤0.01%	455

Other funds holding RNTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLF

Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

LMR Partners's RNTX Position: Q3 2018 in Review

LMR Partners sold out of Rein Therapeutics (RNTX) in Q3 2018, closing a stake of 653 shares — an estimated $71K sold.

LMR Partners first reported a position in RNTX in Q2 2018 and held it in 1 quarter. The position peaked at $71K in Q2 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q3 2018.

LMR Partners reported no remaining Rein Therapeutics position as of Q3 2018 after selling out during the quarter.
LMR Partners sold 653 Rein Therapeutics shares in Q3 2018, an estimated $71K.
LMR Partners first reported a position in Rein Therapeutics in Q2 2018 and held it in 1 quarter.
LMR Partners's Rein Therapeutics position peaked at $71K in Q2 2018.
23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2018.

Based on LMR Partners's 13F filing for Q3 2018, filed 14 Nov 2018.